Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant chemother...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports Jg. 13; H. 1; S. 12869 - 14
Hauptverfasser:	Orrù, Sandra, Pascariello, Emanuele, Pes, Barbara, Rallo, Vincenzo, Barbara, Raffaele, Muntoni, Marta, Notari, Francesca, Fancello, Gianfranco, Mocci, Cristina, Muroni, Maria Rosaria, Cossu-Rocca, Paolo, Angius, Andrea, De Miglio, Maria Rosaria
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 08.08.2023 Nature Publishing Group Nature Portfolio
Schlagworte:	631/67 692/53 Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer therapies Chemotherapy Decision making ErbB-2 protein Female Gene expression Humanities and Social Sciences Humans Lymph nodes Lymphatic system Lymphocytes, Tumor-Infiltrating Machine learning Medical prognosis Metastases Microenvironments Monoclonal antibodies multidisciplinary Neoadjuvant Therapy Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Science Science (multidisciplinary) Trastuzumab Trastuzumab - therapeutic use Treatment Outcome Tumor Microenvironment
ISSN:	2045-2322, 2045-2322
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!